Novartis | NVS - Выручка от реализации





Продажи Изменить Дата
AbbVie USD 16.99B 1.99B 2026-06
Amgen USD 10.1B 1.48B 2026-06
AstraZeneca USD 15.38B 90M 2026-06
Bausch Health Companies USD 2.85B 350M 2026-06
Biogen USD 2.74B 490M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Canopy Growth CAD 71.25M 3.29M 2026-03
Corcept Therapeutics USD 256.15M 91.25M 2026-06
Drreddys Laboratories INR 789.05M 86.48B 2026-03
Eli Lilly USD 22.97B 3.17B 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
J&J USD 25.4B 89M 2026-09
Merck USD 16.6B 310M 2026-06
Novartis USD 14.41B 1.3B 2026-06
Novartis USD 13.11B 750M 2026-03
Pacira USD 192.4M 15.4M 2026-06
Perrigo USD 1.02B 51M 2026-06
Pfizer USD 15.03B 530M 2026-06
Phibro Animal Health USD 373.91M 10.02M 2025-12
Prestige Brands USD 265.71M 15.91M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sanofi EUR 11.95B 710M 2026-06
Sanofi EUR 12.14B 65M 2026-03
Supernus Pharmaceuticals USD 219.1M 11.39M 2026-06
Zoetis USD 2.5B 200M 2026-06